Model |
Cutoff |
Patients |
HVPG-proved CSPH patients |
Performance |
CSPH risk model
(n=151)
|
Rule out
CSPH risk <-0.68
|
53 (35.1%)
|
5
|
SE: 93.6%
NPV: 90.6%
|
|
Grey zone |
34 (22.5%)¶
|
15 |
50.0% of patients
with CSPH |
|
Rule in
CSPH risk >0
|
64 (42.3%)
|
58
|
SP: 91.8%
PPV: 90.6%
|
Baveno VII criteria
(n=151)
|
Rule out
LSM ≤15 kPa and PLT ≥150×109/L
|
46 (30.4%)
|
3
|
SE: 96.9%
NPV: 94.6%
|
|
Grey zone |
76 (50.3%)¶
|
48 |
63.1% of patients
with CSPH |
|
Rule in
LSM ≥25 kPa
|
29 (19.2%)
|
27
|
SP: 98.2%
PPV: 96.0%
|